BiotechTube
UGA Biopharma

UGA Biopharma

Munich, Germany· Est.
ugabiopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

UGA Biopharma GmbH is a private, revenue-generating service provider and product supplier in the biopharmaceutical contract development and manufacturing (CDMO) space. Based near Berlin, the company focuses on enabling the production of advanced biologics and biosimilars through its proprietary cell line development platform and CHO Prime® media/feed systems. It has completed over 50 customer projects and serves a global clientele, positioning itself as a specialized partner for efficient bioprocess development. The company is ISO 9001 certified and actively engages in industry conferences and scientific collaborations.

OncologyImmunology

Technology Platform

Proprietary CHO Prime® platform for cell line development, including specially adapted CHO host cell lines, optimized CHO Prime® Medium and matched Feed systems, and integrated services for upstream/downstream processing and analytics.

Opportunities

The global expansion of the biologics and biosimilars market, particularly in oncology and immunology, drives demand for specialized, cost-effective development services and optimized cell culture products.
The expiration of patents on major biologic drugs creates a sustained pipeline of biosimilar projects requiring efficient cell line development.

Risk Factors

Heavy reliance on CHO cell technology faces risk if alternative production systems gain prominence.
The company operates in a competitive CDMO and bioprocessing supplies market against larger, resource-rich players, posing client acquisition and retention challenges.

Competitive Landscape

UGA Biopharma competes in the specialized CDMO and bioprocessing supplies segment, facing competition from large, full-service CDMOs (e.g., Lonza, Samsung Biologics) and other niche cell line development firms. Its differentiation is based on its proprietary CHO Prime® platform, focus on cost-effectiveness, and integrated service-product offerings for biosimilar and biologic developers.

More companies in Biologics / Biosimilars →More companies in Germany →